Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

NCT05218889 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
PDAC - Pancreatic Ductal Adenocarcinoma
Pancreas Cancer
Pancreatic Neoplasms

Interventions

DRUG: surufatinib + camrelizumab + nab-paclitaxel + S-1
DRUG: nab-paclitaxel + gemcitabine

Sponsor

Chinese PLA General Hospital